CYP2C19 and PON1 polymorphisms regulating clopidogrel bioactivation in Chinese, Malay and Indian subjects

Paraoxonase-1 Q192R Polymorphism and Antiplatelet Effects of Clopidogrel in Patients Undergoing Elective Coronary Stent Placement

(2011) Dietmar Trenk et al.   Circulation-Cardiovascular Genetics

Effect of Paraoxonase-1 Polymorphism on Clinical Outcomes in Patients Treated With Clopidogrel After an Acute Myocardial Infarction

(2011) T Simon et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting

(2011) D. Sibbing et al.   EUROPEAN HEART JOURNAL

Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement

(2010) Dirk Sibbing et al.   CIRCULATION

Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI

(2010) Jessica L. Mega et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Genetic Variation in Metabolizing Enzyme and Transporter Genes: Comprehensive Assessment in 3 Major East Asian Subpopulations With Comparison to Caucasians and Africans

(2010) Michael Man et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Genotyping

(2010) Paul A. Gurbel et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Clopidogrel Loading Dose Adjustment According to Platelet Reactivity Monitoring in Patients Carrying the 2C19*2Loss of Function Polymorphism

(2010) Laurent Bonello et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Impact of Cytochrome P450 2C19 Loss-of-Function Polymorphism and of Major Demographic Characteristics on Residual Platelet Function After Loading and Maintenance Treatment With Clopidogrel in Patients Undergoing Elective Coronary Stent Placement

(2010) Willibald Hochholzer et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy

(2010) D. SIBBING et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Paraoxonase-1 is a major determinant of clopidogrel efficacy

(2010) Heleen J Bouman et al.   NATURE MEDICINE

Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy

(2009) Alan R. Shuldiner   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Assessment of CYP2C19 genetic polymorphisms in a korean population using a simultaneous multiplex pyrosequencing method to simultaneously detect the CYP2C19*2, CYP2C19*3, and CYP2C19*17 alleles

(2009) K.-A. Kim et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

TheCYP2C19*2andCYP2C19*3polymorphisms are associated with high post-treatment platelet reactivity in Asian patients with acute coronary syndrome

(2009) I.-S. KIM et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

The Effect of CYP2C19 Polymorphism on the Pharmacokinetics and Pharmacodynamics of Clopidogrel: A Possible Mechanism for Clopidogrel Resistance

(2008) KA Kim et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Interethnic Variability of Plasma Paraoxonase (PON1) Activity towards Organophosphates and PON1 Polymorphisms among Asian Populations━A Short Review

(2008) Safiyya MOHAMED ALI et al.   INDUSTRIAL HEALTH

Cytochrome P-450 Polymorphisms and Response to Clopidogrel

(2008) Jessica L. Mega et al.   NEW ENGLAND JOURNAL OF MEDICINE